Compare EVO & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | CTMX |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | Germany | United States |
| Employees | 4553 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.1M | 977.1M |
| IPO Year | N/A | 2015 |
| Metric | EVO | CTMX |
|---|---|---|
| Price | $3.06 | $3.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $7.00 | ★ $12.10 |
| AVG Volume (30 Days) | 95.4K | ★ 3.4M |
| Earning Date | 04-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | $10.05 | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $1.72 |
| 52 Week High | $4.80 | $8.21 |
| Indicator | EVO | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 36.51 |
| Support Level | $2.88 | $3.83 |
| Resistance Level | $3.78 | $3.91 |
| Average True Range (ATR) | 0.12 | 0.25 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 33.33 | 3.96 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.